Why liraglutide helps blood sugar even before you lose weight
Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 589 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 589 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Publication
Journal
Diabetes
Year
2023
Authors
M. Mashayekhi, Hui Nian, Dustin Mayfield, Jessica K Devin, Jorge L. Gamboa, Chang Yu, Heidi J Silver, K. Niswender, James M. Luther, Nancy J. Brown
Related Content
Claims (6)
In people with obesity and prediabetes, the drug liraglutide lowers blood glucose levels after fasting and after meals within two weeks, even without weight loss. This effect is not seen with other approaches that increase GLP-1 naturally or reduce calories, suggesting liraglutide works through a distinct mechanism.
Blocking the GLP-1 receptor with exendin(9-39) eliminates the improvements in insulin sensitivity and blood glucose control that result from liraglutide treatment in people with obesity and prediabetes, indicating that these effects require GLP-1 receptor activity.
GLP-1 receptor agonists trigger changes in the body that occur even when weight loss is accounted for, suggesting these drugs have effects beyond reducing body weight.
In people with obesity and prediabetes, a daily dose of liraglutide improves how the body responds to insulin within two weeks, before any significant weight loss occurs, and this improvement is blocked when the GLP-1 receptor is inhibited.
In people with obesity and prediabetes, a drug called sitagliptin increases certain gut hormones but does not improve how the body responds to insulin or lower fasting blood sugar. This suggests that simply boosting these natural hormones is not enough—direct pharmacological activation of their receptors is needed for metabolic improvement.